Upping the ante on antibodies
- 1 September 2005
- journal article
- Published by Springer Nature in Nature Biotechnology
- Vol. 23 (9), 1065-1072
- https://doi.org/10.1038/nbt0905-1065
Abstract
The current generation of antibodies has done more than make a few companies rich. It has laid the groundwork for ambitious companies to move to maturity.Keywords
This publication has 3 references indexed in Scilit:
- Next-generation monoclonals less profitable than trailblazers?Nature Biotechnology, 2005
- Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific AntibodyJournal of Biological Chemistry, 2004
- Antibody engineering for therapeuticsCurrent Opinion in Structural Biology, 2003